archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    Half Year Financial Report 2006 07 CSL Half Year Financial Report 2006 07 Melbourne Australia 13 04 2007 Strong profit growth in the first half of the year reflected a solid trading performance by CSL Behring through increased sales and better operating margins Total revenue grew 10 to 1 6 billion compared to the same period last financial year Net profit after tax increased 46 to 257 million Your Directors

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199979139483/prdetail.htm (2014-01-05)
    Open archived version from archive


  • News Archive
    IVUS is a technique in which a tiny ultrasound probe is inserted into the coronary arteries to determine the change in plaque during treatment Coronary angiography is an X ray examination of the blood vessels Dr Andrew Cuthbertson CSL s Chief Scientific Officer advised that 183 patients had received placebo n 60 40 mg kg n 111 or 80 mg kg n 12 of CSL 111 He noted that the higher dosage of CSL 111 was discontinued early because of transient liver function test abnormalities but the 40mg kg dose was safe and generally well tolerated CSL confirmed that the results were based on data from 145 patients who had 2 sequential IVUS procedures The main findings were that there was a reduction in coronary plaque volume after infusions of CSL 111 of 3 4 percent and after placebo of 1 6 percent which were not statistically significantly different However when compared to baseline the reduction for patients infused with CSL 111 was statistically significant p 0 001 but this was not the case in the placebo group Other assessments of the plaque such as characterization indexes or changes in plaque that are different than volume measurements on IVUS and coronary score on QCA were significantly different between CSL 111 and placebo Interestingly the difference in coronary score between patients that had 4 weeks of CSL 111 and those given placebo was similar to those observed after two years of statin treatment compared with no statin Overall these results strongly suggest that CSL 111 is biologically active and that short term infusions of CSL 111 result in a rapid favourable effect on coronary atherosclerotic plaque said Dr Tardif Principal Investigator Montreal Heart Institute These data strongly support the conduct of further clinical studies to assess whether CSL 111 will provide

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739532/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Aventis that had facilitated an extension of the arrangements with Bayer for the supply of Helixate FS CSL Behring s recombinant Factor VIII product CSL advised that the previous agreement with Bayer on Helixate FS would have expired in 2009 with the new arrangement securing supply for a further eight years until the end of 2017 CSL reported that in the last financial year Helixate FS generated revenues of US 340 million CSL advised that it had agreed to pay Sanofi Aventis the Contingent Payment of US 250m1 and the Deferred Payment of US 65m2 earlier than originally agreed when CSL acquired Aventis Behring in 2004 This agreement with Sanofi Aventis has enabled CSL to independently negotiate with Bayer the sublicensing terms of certain intellectual property related to recombinant Factor VIII to secure the long term supply of Helixate FS and to facilitate the settlement of litigation against Bayer CSL also noted that a number of other outstanding matters that had remained unresolved with Sanofi Aventis stemming from the original 2004 acquisition of Aventis Behring had also now been resolved Dr McNamee commented that he was pleased that all parties had gained substantially from the outcome of complex negotiations which had resulted in securing the long term supply of CSL Behring s key lifesaving product Helixate FS for the benefit of the patient communities that the Company serves 1 CSL had made provision for this Contingent Payment at the time of its full year result announcement in August 2006 CSL had agreed at the time of the acquisition of Aventis Behring in March 2004 to pay US 250m to Aventis now Sanofi Aventis on 31 March 2008 if the volume weighted average price of CSL s shares for any 60 consecutive trading day period during the six months prior to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562739094/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    pandemic influenza vaccine clinical trial program These results will enable submission of a dossier to the TGA for the registration of a pandemic influenza vaccine The latest clinical studies confirm that two doses of 30 micrograms of antigen with the addition of an aluminium adjuvant or immune stimulant are required to produce a strong immune response against the H5N1 bird flu virus The vaccine was found to be safe and well tolerated in the study population of adults aged 18 to 65 Results of a subsequent study undertaken in infants young children and the elderly are expected to be available later this year CSL is delighted to reassure the community that the Australian Government will be able to respond with CSL s vaccine in the event that an influenza pandemic affects Australia Dr Andrew Cuthbertson Chief Scientific Officer at CSL said today The Australian Government has contributed 7 17 million towards the costs of CSL s pandemic vaccine development program including the vaccine trials CSL s future research and development Program for pandemic influenza is ongoing as part of its role as Australia s major supplier of influenza vaccines and the only supplier based in the Southern Hemisphere While CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562738896/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    rights and options to Wyeth for the use of CSL s ISCOMATRIX adjuvant in a number of Wyeth s investigational vaccine programs This agreement further endorses the broad use of ISCOMATRIX adjuvant in novel vaccine development programs said Dr Andrew Cuthbertson Chief Scientific Officer at CSL We are delighted to work with Wyeth a company with a strong commitment to development of innovative vaccines in the human health arena and to add them to our existing ISCOMATRIX adjuvant partners Under the terms of the agreement CSL could receive an upfront options and milestone payments that total up to more than US 90m as well as royalties on future product sales CSL will supply all of Wyeth s requirements for ISCOMATRIX adjuvant for development and commercialisation Other financial terms were not disclosed About ISCOMATRIX Adjuvant An adjuvant is used to improve or modify the body s immune response to an antigen Adjuvants play an important role in the development of vaccines by potentially generating broader more potent and durable immune responses The ISCOMATRIX adjuvant is a saponin based adjuvant with both antigen delivery and immunomodulatory properties making it ideally suited for use in the development of a new generation of human

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562741382/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Home Newsroom News Archive Strong Trading Conditions in International Plasma Therapies Strong Trading Conditions in International Plasma Therapies Melbourne Australia 13 12 2006 CSL Limited today lifted its financial guidance for the 2006 2007 financial year following strong trading conditions in the international plasma therapies market The company now expects a net profit after tax of between 440m and 460m an increase of approximately 10 above guidance provided at the

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562741354/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Generation of Women Melbourne Australia 29 11 2006 CSL Limited welcomes today s announcement by the Prime Minister and the Minister for Health that the Commonwealth Government will make GARDASIL the world s first cervical cancer vaccine available for school girls aged 12 to 18 years under the Government funded National Immunisation Program NIP In addition a free vaccine program for women aged 19 26 will be delivered by General Practitioners In total over 1 million Australian women and girls will be covered by the program CSL advises that it will be able to deliver the vaccine in time for the immunisation program to commence in 2007 CSL has worked closely with the Government to make GARDASIL available to Australian women as soon as possible and this has involved fine tuning various aspects of our submission including some areas that have overall cost implications CSL s CEO Dr Brian McNamee said today The combination of a national immunisation program with GARDASIL and regular two yearly pap smears means that we could substantially reduce the burden of cervical cancer and pre cancers State and Federal Governments now need to move to implement this program quickly he said The schools based program

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562741233/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    News Archive CSL announces acquisition of CytoGam from MedImmune CSL announces acquisition of CytoGam from MedImmune Melbourne Australia 09 11 2006 Melbourne Australia CSL Limited has announced that its subsidiary ZLB Behring has reached an agreement with MedImmune Inc to acquire CytoGam cytomegalovirus immune globulin intravenous human and related assets CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus CMV which is indicated for prophylaxis against CMV disease associated with transplantation of the kidney lung liver pancreas and heart CMV is the most common cause of infection occurring after any solid organ transplant contributing significantly to morbidity and mortality in organ transplant recipients CSL advised that ZLB Behring will acquire CytoGam for US 120 million in cash US 70 million of which is subject to achievement of sales milestones CytoGam fits well in ZLB Behring s immunoglobulin portfolio said Peter Turner president of ZLB Behring We are proud of our heritage of providing a reliable quality supply of critical therapies to small patient populations We look forward to continuing that heritage with transplant patients The acquisition includes CytoGam and related assets including patents and trademarks manufacturing contracts and government authorisations associated with the product No employees will transfer

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562741147/prdetail.htm (2014-01-05)
    Open archived version from archive